目的 探討血脂康膠囊聯(lián)合替格瑞洛治療穩(wěn)定性冠心病的臨床療效。方法 選取2021年10月—2024年10月在合肥市第二人民醫(yī)院接受治療的120例穩(wěn)定性冠心病患者，依據(jù)用藥方案的差異將患者分為對照組和治療組，每組各60例。對照組口服替格瑞洛片進行治療，給藥劑量為90 mg/次，每日2次；治療組在對照組治療基礎上聯(lián)合應用血脂康膠囊口服治療，單次劑量為0.6 g，每日2次給藥，均為餐后服用。兩組患者均接受為期2個月的連續(xù)治療。觀察兩組臨床療效，并比較治療前后中醫(yī)證候評分、西雅圖心絞痛量表（SAQ）評分，24 h缺血發(fā)作次數(shù)和最長持續(xù)時間，血清脂蛋白相關磷脂酶A2（Lp-PLA2）、肌酸激酶同工酶MB（CK-MB）和細胞間黏附分子-1（ICAM-1）水平變化。結果 臨床療效分析顯示，治療組以95.00%的總有效率顯著優(yōu)于對照組的81.67%（P＜0.05）。治療后，兩組中醫(yī)證候評分較前顯著降低，而SAQ評分顯著升高（P＜0.05）；治療后，治療組中醫(yī)證候評分低于對照組，SAQ評分高于對照組（P＜0.05）。治療后兩組24 h監(jiān)測顯示缺血發(fā)作次數(shù)與單次最長持續(xù)時間均顯著縮短（P＜0.05）；治療后治療組缺血發(fā)作次數(shù)與單次最長持續(xù)時間均低于對照組（P＜0.05）。治療后兩組Lp-PLA2、CK-MB及ICAM-1水平均呈現(xiàn)顯著下降（P＜0.05）；治療后，治療組Lp-PLA2、CK-MB及ICAM-1水平低于對照組（P＜0.05）。結論 血脂康膠囊聯(lián)合替格瑞洛治療穩(wěn)定性冠心病療效顯著，不但可顯著改善患者心肌缺血癥狀和生活質量，而且能促進血清學指標的修復，具有重要臨床推廣價值。

Objective To evaluate the clinical efficacy of Xuezhikang Capsules combined with ticagrelor in treatment of stable coronary heart disease. Methods A total of 120 patients with stable coronary heart disease who were treated at Hefei Second People’s Hospital from October 2021 to October 2024 were selected. According to the differences in medication regimens, the patients were divided into control group and treatment group, with 60 cases in each group. Patients in control group were treated with oral Ticagrelor Tablets at a dose of 90 mg each time, twice daily. Patients in control group were combined with the oral administration of Xuezhikang Capsules on the basis of treatment in control group. The single dose was 0.6 g, administered twice daily, both after meals. Both groups of patients received continuous treatment for a period of two months. The clinical efficacy of two groups was observed, and the TCM syndrome score, SAQ score, the number of 24 h ischemic attacks and the longest duration, as well as the changes in the levels of serum Lp-PLA2, CK-MB, and ICAM-1 before and after treatment were compared. Results Clinical efficacy analysis showed that the treatment group had a total effective rate of 95.00%, which was significantly better than 81.67% in the control group (P < 0.05). After treatment, the TCM syndrome scores of both groups were significantly lower than before, but the SAQ scores were significantly increased (P < 0.05). After treatment, the TCM syndrome score of the treatment group was lower than that of the control group, and the SAQ score was higher than that of the control group (P < 0.05). 24 h Monitoring in both groups after treatment showed that the number of ischemic attacks and the maximum duration of a single attack were significantly shortened (P < 0.05). After treatment, the number of ischemic attacks and the longest duration of a single attack in the treatment group were both lower than those in the control group (P < 0.05). After treatment, the levels of Lp-PLA2, CK-MB, and ICAM-1 in both groups decreased significantly (P < 0.05). After treatment, the levels of Lp-PLA2, CK-MB, and ICAM-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Xuezhikang Capsules combined with ticagrelor has a remarkable therapeutic effect on stable coronary heart disease, not only significantly improve the myocardial ischemia symptoms and life quality, but also promote the repair of serological indicators, which has important clinical promotion value.

R972

合肥市衛(wèi)生健康委醫(yī)學科研項目（Hwk2023zd009）